FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment
Go back to FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.04 -1.72 (3.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.76 | 52 Week High | $45.58 | |||
| Open | $51.38 | 52 Week Low | $37.82 | |||
| Day High | $51.67 | P/E | N/A | |||
| Day Low | $50.01 | EPS | $0.00 | |||
| Volume | 5,345,175 | |||||
